The story of Viagra and its creator , copyright, presents a complex picture for prospective investors. While the iconic drug initially fueled enormous profits , its patent has expired , leading to rival options flooding the arena. This reduction in pricing presents a significant challenge for copyright and any fund considering a significant positio